News | September 16, 2014

DrugDev CEO Ibraheem Mahmood Shortlisted For 2014 SCRIP Awards

Source: DrugDev

Global change agent pushing far more medicines through development with modern technologies that enable clinical trial sponsors, CROs and investigators to do more clinical trials together

DrugDev and its President and CEO Ibraheem (Ibs) Mahmood are finalists for the 10th Annual SCRIP Awards. The awards recognize innovation and excellence in the international biopharmaceutical industry. Winners chosen by a panel of luminaries from across the sector will be announced at a gala in London on 3 December.

DrugDev is a leading provider of technology-driven solutions that help investigators, sponsors and CROs do more clinical trials together. DrugDev brings together the largest online network of clinical trial sites, the leading investigator identification and start-up platform, the industry’s best trial optimization system, and the leading investigator payment capabilities to transform the way drug developers find, engage and pay doctors to run clinical trials.

Ibs Mahmood defines the DrugDev vision to provide technologies and services to clinical trial doctors that help the industry conduct trials faster, smarter and cheaper. Over the last two years Ibs led the acquisitions of the leading investigator payment and site contracting system in CFS Clinical and the award-winning TrialNetworks platform of clinical operations apps, and raised an initial $50m investment from Invesco Perpetual. Also this year Ibs was named one of the PharmaVOICE 100 most inspiring people in life sciences.

Ibs said, “We’re very grateful the SCRIP judges recognize the value of DrugDev’s mission to bring real disruption to the way drugs are developed. We’re passionate about making it easier for trial sponsors, CROs and sites to collaborate on many more clinical trials that evaluate many more new drugs, and bring those drugs to the millions of patients worldwide who desperately need them.”

About DrugDev
DrugDev simplifies life at the clinical trial site through technology and enables sponsors, CROs and investigators to do more trials together. DrugDev creates and drives standards which promote collaboration, improve quality, shorten timelines and reduce cost. Our solutions include the largest global network of active investigators; the industry’s leading grant payment and site contracting system in CFS Clinical; and, the award-winning TrialNetworks platform of clinical operations apps. DrugDev provides Hosted Data Solutions for clinical trials including hosting the Investigator Databank for Novartis, Janssen, Merck, Lilly and Pfizer. For more information, visit drugdev.com.

Source: DrugDev